(Q54128061)

25 May 2018

review article

1 reference

title

The cardiovascular dysmetabolic syndrome. (English)

1 reference

25 May 2018

1 reference

T C Fagan

1

1 reference

25 May 2018

P C Deedwania

series ordinal

2

1 reference

25 May 2018

language of work or name

English

0 references

publication date

1 July 1998

1 reference

25 May 2018

American Journal of Medicine

published in

1 reference

25 May 2018

volume

105

1 reference

25 May 2018

issue

1A

1 reference

25 May 2018

page(s)

77S-82S

1 reference

25 May 2018

Banting lecture 1988. Role of insulin resistance in human disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Diabetes mellitus and cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Fasting hyperinsulinemia and cardiovascular disease risk factors in nondiabetic adults: stronger associations in lean versus obese subjects. Atherosclerosis Risk in Communities Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Insulin resistance implications for type II diabetes mellitus and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The cellular and molecular mechanisms of diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Impaired glucose tolerance in the U.S. population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Metformin Associated Lactic Acidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Hepatic dysfunction associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

ACE inhibitors in elderly patients with hypertension. Special considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Endothelial function in health and disease: new insights into the genesis of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The oxidation hypothesis of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Epidemiologic aspects of lipid abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Triglycerides and atherogenic lipoproteins: rationale for lipid management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900216-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00216-2

1 reference

25 May 2018

1 reference

25 May 2018